Avanos Medical Financial Statements (AVNS)
|
|
Report date
|
|
|
01.11.2023 |
21.02.2024 |
02.05.2024 |
31.07.2024 |
30.10.2024 |
|
30.10.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
171.3 |
173.3 |
166.1 |
171.7 |
170.4 |
|
681.5 |
Operating Income, bln rub |
|
|
1.20 |
22.2 |
7.40 |
16.1 |
12.0 |
|
57.7 |
EBITDA, bln rub |
? |
|
13.1 |
30.3 |
18.9 |
23.0 |
24.4 |
|
96.6 |
Net profit, bln rub |
? |
|
-3.70 |
10.5 |
-0.900 |
1.80 |
4.30 |
|
15.7 |
|
OCF, bln rub |
? |
|
29.1 |
12.7 |
-8.00 |
27.8 |
23.0 |
|
55.5 |
CAPEX, bln rub |
? |
|
3.90 |
5.90 |
4.10 |
5.90 |
3.00 |
|
18.9 |
FCF, bln rub |
? |
|
25.2 |
6.80 |
-12.1 |
21.9 |
20.0 |
|
36.6 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
94.3 |
75.2 |
87.4 |
79.5 |
80.9 |
|
323.0 |
Cost of production, bln rub |
|
|
75.8 |
75.9 |
71.3 |
76.1 |
77.5 |
|
300.8 |
R&D, bln rub |
|
|
6.10 |
6.80 |
7.00 |
6.30 |
7.20 |
|
27.3 |
Interest expenses, bln rub |
|
|
4.70 |
3.30 |
3.10 |
3.10 |
3.20 |
|
12.7 |
|
Assets, bln rub |
|
|
1 725 |
1 692 |
1 661 |
1 658 |
1 656 |
|
1 656 |
Net Assets, bln rub |
? |
|
1 222 |
1 236 |
1 228 |
1 222 |
1 230 |
|
1 230 |
Debt, bln rub |
|
|
306.7 |
209.1 |
214.7 |
218.3 |
202.2 |
|
202.2 |
Cash, bln rub |
|
|
107.1 |
87.7 |
75.8 |
92.2 |
89.0 |
|
89.0 |
Net debt, bln rub |
|
|
199.6 |
121.4 |
138.9 |
126.1 |
113.2 |
|
113.2 |
|
Ordinary share price, rub |
|
|
20.2 |
22.4 |
19.9 |
19.9 |
24.0 |
|
21.5 |
Number of ordinary shares, mln |
|
|
46.8 |
46.2 |
46.2 |
45.9 |
46.0 |
|
46.0 |
|
Market cap, bln rub |
|
|
946 |
1 036 |
920 |
914 |
1 105 |
|
991 |
EV, bln rub |
? |
|
1 146 |
1 158 |
1 059 |
1 040 |
1 219 |
|
1 104 |
Book value, bln rub |
|
|
188 |
201 |
200 |
201 |
215 |
|
215 |
|
EPS, rub |
? |
|
-0.08 |
0.23 |
-0.02 |
0.04 |
0.09 |
|
0.34 |
FCF/share, rub |
|
|
0.54 |
0.15 |
-0.26 |
0.48 |
0.43 |
|
0.80 |
BV/share, rub |
|
|
4.03 |
4.34 |
4.33 |
4.39 |
4.66 |
|
4.66 |
|
EBITDA margin, % |
? |
|
7.65% |
17.5% |
11.4% |
13.4% |
14.3% |
|
14.2% |
Net margin, % |
? |
|
-2.16% |
6.06% |
-0.54% |
1.05% |
2.52% |
|
2.30% |
FCF yield, % |
? |
|
3.87% |
1.41% |
1.45% |
4.57% |
3.31% |
|
3.69% |
ROE, % |
? |
|
-4.53% |
-5.00% |
-5.07% |
0.63% |
1.28% |
|
1.28% |
ROA, % |
? |
|
-3.21% |
-3.65% |
-3.74% |
0.46% |
0.95% |
|
0.95% |
|
P/E |
? |
|
-17.1 |
-16.8 |
-14.8 |
118.7 |
70.4 |
|
63.1 |
P/FCF |
|
|
25.9 |
71.0 |
69.2 |
21.9 |
30.2 |
|
27.1 |
P/S |
? |
|
1.26 |
1.47 |
1.35 |
1.34 |
1.62 |
|
1.45 |
P/BV |
? |
|
5.02 |
5.16 |
4.59 |
4.54 |
5.15 |
|
4.62 |
EV/EBITDA |
? |
|
14.6 |
16.9 |
14.7 |
12.2 |
12.6 |
|
11.4 |
Debt/EBITDA |
|
|
2.54 |
1.77 |
1.92 |
1.48 |
1.17 |
|
1.17 |
|
R&D/CAPEX, % |
|
|
156.4% |
115.3% |
170.7% |
106.8% |
240.0% |
|
144.4% |
|
CAPEX/Revenue, % |
|
|
2.28% |
3.40% |
2.47% |
3.44% |
1.76% |
|
2.77% |
|
Avanos Medical shareholders |